ArticleUnited European gastroenterology journal2018

Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists.

Martine De Vos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.